REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

The treatment of metastatic colorectal cancer (mCRC) has evolved considerably over the past two decades [1, 2]. Two randomized trials in the first-line setting compared chemotherapy with bevacizumab versus anti-epidermal growth factor (EGFR) monoclonal antibodies for patients with wild-type (WT) KRAS exon 2 mCRC [3, 4].